Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1347-1350

  Disis, Mary L ^a,c   Schiffman, Kathy ^a   Gooley, Theodore A ^b   McNeel, Douglas G ^a   Rinn, Kristine ^a   Knutson, Keith L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CELLULAR IMMUNITY; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; FEMALE; HUMAN; IMMUNIZATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; OVARY CANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SKIN TESTS; T-LYMPHOCYTES;

EID: 0034006703     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA, 92: 11810-11813, 1995.
2. Coulie, P. G., Brichard, V., Van-Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J. Exp. Med., 180: 35-42, 1994.
3. Disis, M., Grabstein, K., Sleath, P., and Cheever, M. A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res., 5: 1289-1297, 1999.
4. Disis, M., and Cheever, M. HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol., 18: 37-45, 1998.
5. Gordon, E. H., Krouse, H. A., Kinney, J. L., Stiehm, E. R., and Klaustermeyer, W. B. Delayed cutaneous hypersensitivity in normals: choice of antigens and comparison to in vitro assays of cell-mediated immunity. J. Allergy Clin. Immunol., 72: 487-494, 1983.
6. Hsueh, E. C., Gupta, R. K., Qi, K., and Mortem, D. L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oricol., 16: 2913-2920, 1998.
7. Jones, R. C., Kelley, M., Gupta, R. K., Nizze, J. A., Ye, R., Leopoldo, Z., Qi, K., Stern, S., and Morton, D. L. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann. Surg. Oncol., 3: 437-445, 1996.